| 2024-05-08 |
股东大会：
将于2024-06-12召开股东大会
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2020-05-07 |
详情>>
股本变动：
变动后总股本32980.58万股
|
| 2020-05-07 |
详情>>
业绩披露：
2020年一季报每股收益1.15美元,归母净利润3.78亿美元,同比去年增长115.70%
|
| 2020-03-18 |
除权日：
美东时间 2020-04-15 每股派息0.74美元
|
| 2020-02-18 |
详情>>
业绩披露：
2019年年报每股收益-16.02美元,归母净利润-52.71亿美元,同比去年增长-2.49%
|
| 2020-02-10 |
财报披露：
美东时间 2020-02-10 盘前发布财报
|
| 2020-01-24 |
除权日：
美东时间 2020-02-13 每股派息0.74美元
|
| 2019-11-05 |
详情>>
业绩披露：
2019年三季报(累计)每股收益-15.04美元,归母净利润-49.54亿美元,同比去年增长-487.71%
|
| 2019-10-25 |
除权日：
美东时间 2019-11-12 每股派息0.74美元
|
| 2019-08-08 |
详情>>
业绩披露：
2019年中报每股收益-12.63美元,归母净利润-41.67亿美元,同比去年增长-417.64%
|
| 2019-07-19 |
除权日：
美东时间 2019-08-12 每股派息0.74美元
|
| 2019-05-07 |
详情>>
业绩披露：
2019年一季报每股收益-7.25美元,归母净利润-24.08亿美元,同比去年增长-624.21%
|
| 2019-05-03 |
除权日：
美东时间 2019-05-13 每股派息0.74美元
|
| 2019-03-22 |
股东大会：
将于2019-05-01召开股东大会
会议内容 ▼▲
- 1.To elect by separate resolutions Nesli Basgoz, M.D., Joseph H. Boccuzi, Christopher W. Bodine, Adriane M. Brown, Christopher J. Coughlin, Carol Anthony (John) Davidson, Thomas C. Freyman, Michael E. Greenberg, PhD, Robert J. Hugin, Peter J. McDonnell, M.D. and Brenton L. Saunders as members of the Board of Directors to hold office until the 2020 Annual General Meeting of Shareholders or until each of their respective successors is duly elected and qualified;
2.To approve, in a non-binding vote, Named Executive Officer compensation;
3.To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company's auditor for the fiscal year ending December 31, 2019 and to authorize, in a binding vote, the Board of Directors, acting through its Audit and Compliance Committee, to determine PricewaterhouseCoopers LLP's remuneration;
4.To renew the authority of the directors of the Company (the "Directors") to issue shares;
5.To renew the authority of the Directors to issue shares for cash without first offering shares to existing shareholders;
6.To authorize the Directors to allot new shares up to an additional 5% for cash in connection with an acquisition or other capital investment;
7.To consider a shareholder proposal (Proposal No. 6) to require an independent Board Chairman with immediate effect, as detailed in the Proxy Statement, if properly presented at the meeting;
|
| 2019-02-15 |
详情>>
业绩披露：
2018年年报每股收益-15.26美元,归母净利润-51.43亿美元,同比去年增长-16.78%
|
| 2019-01-25 |
除权日：
美东时间 2019-02-14 每股派息0.74美元
|
| 2018-10-31 |
详情>>
业绩披露：
2018年三季报(累计)每股收益-2.5美元,归母净利润-8.43亿美元,同比去年增长88.69%
|
| 2018-10-26 |
除权日：
美东时间 2018-11-09 每股派息0.72美元
|
| 2018-08-03 |
详情>>
业绩披露：
2018年中报每股收益-2.39美元,归母净利润-8.05亿美元,同比去年增长76.53%
|
| 2018-07-30 |
除权日：
美东时间 2018-08-16 每股派息0.72美元
|
| 2018-07-23 |
详情>>
内部人交易：
Ling Karen股份减少715.00股
|
| 2018-05-03 |
除权日：
美东时间 2018-05-17 每股派息0.72美元
|
| 2018-05-03 |
详情>>
业绩披露：
2018年一季报每股收益-0.99美元,归母净利润-3.33亿美元,同比去年增长87.38%
|
| 2018-03-23 |
股东大会：
将于2018-05-02召开股东大会
会议内容 ▼▲
- 1.To elect by separate resolutions Nesli Basgoz, M.D., Paul M. Bisaro, Joseph H. Boccuzi, Christopher W. Bodine, Adriane M. Brown, Christopher J. Coughlin, Carol Anthony (John) Davidson, Catherine M. Klema, Peter J. McDonnell, M.D., Patrick J. O’Sullivan, Brenton L. Saunders, and Fred G. Weiss as members of the Board of Directors to hold office until the 2019 Annual General Meeting of Shareholders or until each of their respective successors is duly elected and qualified;
2.To approve, in a non-binding vote, Named Executive Officer compensation;
3.To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s auditor for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the Board of Directors, acting through its Audit and Compliance Committee, to determine PricewaterhouseCoopers LLP’s remuneration;
4.To renew the authority of the directors of the Company (the “Directors”) to issue shares;
5.To renew the authority of the Directors to issue shares for cash without first offering shares to existing shareholders;
6.To authorize the Directors to allot new shares up to an additional 5% for cash in connection with an acquisition or other capital investment;
7.To consider a shareholder proposal to require an independent Board Chairman (Proposal No. 6), as detailed in the Proxy Statement, if properly presented at the meeting;
|
| 2018-02-16 |
详情>>
业绩披露：
2017年年报每股收益-13.19美元,归母净利润-44.04亿美元,同比去年增长-129.97%
|
| 2018-02-08 |
除权日：
美东时间 2018-02-27 每股派息0.72美元
|
| 2017-10-27 |
除权日：
美东时间 2017-11-16 每股派息0.70美元
|
| 2017-09-09 |
复牌提示：
2017-09-08 12:33:12 停牌，复牌日期 2017-09-08 12:46:52
|
| 2017-08-02 |
除权日：
美东时间 2017-08-16 每股派息0.70美元
|
| 2017-05-08 |
除权日：
美东时间 2017-05-16 每股派息0.70美元
|
| 2017-03-24 |
股东大会：
将于2017-05-04召开股东大会
会议内容 ▼▲
- 1.To re-appoint by separate resolutions Nesli Basgoz, M.D., Paul M. Bisaro, James H. Bloem, Christopher W. Bodine, Adriane M. Brown, Christopher J. Coughlin, Catherine M. Klema, Peter J. McDonnell, M.D., Patrick J. O’Sullivan, Brenton L. Saunders, Ronald R. Taylor and Fred G. Weiss as members of the Board of Directors to hold office until the 2018 Annual General Meeting of Shareholders or until each of their respective successors is duly elected and qualified;
2.To approve, in a non-binding vote, Named Executive Officer compensation;
3.To recommend, in a non-binding vote, whether a shareholder vote to approve the compensation of the Company’s Named Executive Officers should occur every one, two or three years;
4.To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s auditor for the fiscal year ending December 31, 2017 and to authorize, in a binding vote, the Board of Directors, acting through its Audit and Compliance Committee, to determine PricewaterhouseCoopers LLP’s remuneration;
5.To approve the material terms of the performance goals for the purposes of Section 162(m) under the Allergan plc 2017 Annual Incentive Compensation Plan;
6.To consider a shareholder proposal regarding an independent Board Chairman, as detailed in the Proxy Statement, if properly presented at the meeting;
7.to transact such other business as may properly come before the Annual Meeting or any adjournment, postponement or continuation thereof.
|
| 2016-11-03 |
除权日：
美东时间 2017-02-24 每股派息0.70美元
|
| 2016-03-25 |
股东大会：
将于2016-05-05召开股东大会
会议内容 ▼▲
- 1.To elect by separate resolutions Nesli Basgoz, M.D., Paul M. Bisaro, James H. Bloem, Christopher W. Bodine, Christopher J. Coughlin, Michael R. Gallagher, Catherine M. Klema, Peter J. McDonnell, M.D., Patrick J. O’Sullivan, Brenton L. Saunders, Ronald R. Taylor and Fred G. Weiss as members of the Board of Directors to hold office until the 2017 Annual Meeting or until each of their respective successors is duly elected and qualified;
2.To approve, in a non-binding vote, Named Executive Officer compensation;
3.To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent auditor for the fiscal year ending December 31, 2016 and to authorize, in a binding vote, the Board of Directors, acting through the Audit and Compliance Committee, to determine PricewaterhouseCoopers LLP’s remuneration;
4.To approve the amendment of the Company’s (A) Memorandum of Association to make certain administrative amendments and (B) Articles of Association to make certain administrative amendments;
5.To approve the amendment of the Company’s Articles of Association in order to (A) provide for a plurality voting standard in the event of a contested election and (B) grant the Board of Directors sole authority to determine its size;
6.To approve the reduction of company capital;
7.To consider a shareholder proposal, as detailed in the Proxy Statement, if properly presented at the meeting;
8.To consider a second shareholder proposal, as detailed in the Proxy Statement, if properly presented at the meeting;
|
| 2015-04-24 |
股东大会：
将于2015-06-05召开股东大会
会议内容 ▼▲
- 1. To elect Paul M. Bisaro, Nesli Basgoz, M.D., James H. Bloem, Christopher W. Bodine, Christopher J. Coughlin, Michael R. Gallagher, Catherine M. Klema, Peter J. McDonnell, M.D., Patrick J. O’Sullivan, Brenton L. Saunders, Ronald R. Taylor, and Fred G. Weiss as members of the Board of Directors to hold office until the 2016 Annual Meeting or until each of their respective successors is duly elected and qualified.
2. To approve, in a non-binding vote, Named Executive Officer compensation;
3. To ratify, in a non-binding vote, the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2015 and to authorize, in a binding vote, the Board of Directors, acting through the Audit and Compliance Committee, to determine PricewaterhouseCoopers LLP’s remuneration;
4. To pass a special resolution to approve, subject to the approval of the Registrar of Companies in Ireland, the change in name of the Company from Actavis plc to Allergan plc;
5. To approve the Amended and Restated 2013 Incentive Award Plan of Actavis plc;
6. To consider two shareholder proposals, if properly presented at the meeting;
7. To receive the Company’s Irish Statutory Accounts for the fiscal year ended December 31, 2014 and the reports of the directors and auditors thereon, and to review the affairs of the Company;
8. To transact such other business as may properly come before the Annual Meeting or any adjournment, postponement or continuation thereof.
|
| 2015-02-06 |
除权日：
美东时间 2015-02-25 每股派息0.05美元
|
| 2014-10-27 |
除权日：
美东时间 2014-11-18 每股派息0.05美元
|
| 2014-07-21 |
除权日：
美东时间 2014-08-13 每股派息0.05美元
|
| 2014-05-07 |
除权日：
美东时间 2014-05-21 每股派息0.05美元
|
| 2014-02-05 |
除权日：
美东时间 2014-02-26 每股派息0.05美元
|
| 2013-10-29 |
除权日：
美东时间 2013-11-18 每股派息0.05美元
|